Dimitry Nuyten

Hoofd Techniek/Wetenschap/O&O bij ARCUS BIOSCIENCES, INC.

Vermogen: 203 569 $ op 30-04-2024

48 jaar

Health Technology

Consumer Services

Actieve functies van Dimitry Nuyten

Bedrijven	Functie	Begin	Einde
ARCUS BIOSCIENCES, INC.	Hoofd Techniek/Wetenschap/O&O	01-08-2022	-

Bedrijven	Functie	Begin	Einde
NEKTAR THERAPEUTICS	Hoofd Techniek/Wetenschap/O&O	19-07-2021	01-04-2022
PFIZER, INC.	Corporate Officer/Principal	01-07-2013	01-03-2019
BRISTOL-MYERS SQUIBB COMPANY	Hoofd Techniek/Wetenschap/O&O	01-03-2008	01-06-2013
CHINOOK THERAPEUTICS, INC.	Hoofd Techniek/Wetenschap/O&O	22-04-2019	-

University of Groningen	Doctorate Degree
University of Amsterdam	Doctorate Degree

Internationaal

Verenigde Staten	6
Nederland	3

Operationeel

Chief Tech/Sci/R&D Officer	4
Doctorate Degree	2
Corporate Officer/Principal	1

Sectoraal

Health Technology	6
Consumer Services	3

Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Beursgenoteerde bedrijven	4
PFIZER, INC.	Health Technology
BRISTOL-MYERS SQUIBB COMPANY	Health Technology
NEKTAR THERAPEUTICS	Health Technology
ARCUS BIOSCIENCES, INC.	Health Technology

Bedrijven in privébezit	1
Aduro BioTech, Inc. Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.	Health Technology

Bedrijven in privébezit

Health Technology